Holen Sie sich die Stockscreener-App
9.76
2.41%
0.23
Schlusskurs vom Vortag:
$9.53
Offen:
$9.45
24-Stunden-Volumen:
132.73K
Relative Volume:
1.96
Marktkapitalisierung:
$97.97M
Einnahmen:
$23.14M
Nettoeinkommen (Verlust:
$-9.47M
KGV:
-11.06
EPS:
-0.8827
Netto-Cashflow:
$-25.88M
1W Leistung:
+6.09%
1M Leistung:
+11.29%
6M Leistung:
+81.08%
1J Leistung:
-23.75%
1-Tages-Spanne:
$9.25
$9.95
1-Wochen-Bereich:
$8.80
$9.95
52-Wochen-Spanne:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
9.76 | 94.15M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Independent Director of Atara Biotherapeutics Picks Up 272% More Stock - simplywall.st
Atara Biotherapeutics (ATRA) Director Brian Cherry Buys 104,166 Shares - GuruFocus
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com Canada
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares By Investing.com - Investing.com South Africa
Atara Biotherapeutics Director Purchased Shares Worth Over $999K - TradingView
(ATRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics - natlawreview.com
Atara Biotherapeutics director Brian Cherry acquires 104,166 common shares for $999,993.60 - Bitget
Atara Biotherapeutics president and CEO sells $40,882 in shares - Investing.com India
Atara Biotherapeutics (ATRA) employee plans 5,062-share tax sale - stocktitan.net
Atara (ATRA) Results Breakdown: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report Move: The Stock Records a 1.26% Increase at the CloseProfit Growth Outlook - vinanet.vn
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Why (ATRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake - Stock Titan
Atara Biotherapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ATRA | US0465132068 - marketscreener.com
Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com Nigeria
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics cuts costs 87%, extends cash runway to mid-2027 - scanx.trade
Is Atara Biotherapeutics Inc (ATRA) Positioned for Growth After - GuruFocus
Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results - MarketBeat
Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary - TradingView
Atara Biotherapeutics: Q2 Earnings Snapshot - AOL.com
BRIEF-Atara Biotherapeutics Q2 EPS USD -0.32 - TradingView
Atara Biotherapeutics (ATRA) Rallies 3.8% to $8.94, Approaching Resistance at $9.39Volume Nodes - dars.gov.et
Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline? - Kalkine Media
ATRA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a shareEarnings Preview - TradingView
ATRA Q2'26 Earnings: EPS estimate is (0.32) USD - TradingView
ATRA DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Understanding Momentum Shifts in (ATRA) - Stock Traders Daily
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ATRA Q2'26 Earnings: revenue estimate is 550.00K USD - TradingView
Atara Biotherapeutics (ATRA) Projected to Release Earnings on Monday - MarketBeat
Enterprise value to revenue forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView
Atara Biotherapeutics Inc (ATRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EcoR1 Capital LLC Sells 473,590 Shares of Atara Biotherapeutics, Inc. $ATRA - MarketBeat
Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc (ATRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Form 13D/A Atara Biotherapeutics For: 24 July By Investing.com - Investing.com South Africa
Atara Biotherapeutics Inc (ATRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Form 4 Atara Biotherapeutics Inc For: 24 July By Investing.com - Investing.com Nigeria
Atara Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ATRA - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - ACCESS Newswire
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):